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Editors summary 
Nanopore sequencing coupled with a metagenomics framework that effectively 
removes human DNA from samples enables rapid bacterial LRI diagnosis. 
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ABSTRACT 
The gold standard for clinical diagnosis of bacterial lower respiratory infections 
(LRIs) is culture, which has poor sensitivity and is too slow to guide early, targeted 
antimicrobial therapy. Metagenomic sequencing could identify LRI pathogens much 
faster than culture, but methods are needed to remove the large amount of human 
DNA present in these samples for this approach to be feasible. We developed a 
metagenomics method for bacterial LRI diagnosis that features efficient saponin-
based host DNA depletion and nanopore sequencing. Our pilot method was tested on 
40 samples, then optimized, and tested on a further 41 samples. Our optimised 
method (6 hours from sample to result) was 96.6% sensitive and 41.7% specific for 
pathogen detection compared to culture and we could accurately detect antibiotic-
resistance genes. After confirmatory qPCR and pathobiont-specific gene analyses, 
specificity and sensitivity increased to 100%.  Nanopore metagenomics can rapidly 
and accurately characterise bacterial LRIs and might contribute to a reduction in 
broad-spectrum antibiotic use.  
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INTRODUCTION 
Lower respiratory infections (LRIs) caused at least three million deaths worldwide in 2016 
(http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death). They can be 
subdivided into community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), 
bronchitis, bronchiolitis and tracheitis 1. Morbidity and mortality rates vary dependent on 
infection site, pathogen and host factors. In the UK, CAP accounts for approx. 29,000 deaths 
per annum and in the US HAP causes approx. 36,000 deaths per annum 2, 3. The most 
common bacterial CAP pathogens are Streptococcus pneumoniae and Haemophilus 
influenzae, and the most common HAP pathogens are Staphylococcus aureus, 
Enterobacteriaceae and Pseudomonas aeruginosa 4-6. However, multiple bacterial and viral 
pathogen, can cause LRIs, which makes diagnosis and treatment a challenge.
 Respiratory tract infections account for 60% of all antibiotics prescribed in general 
practice in the UK 1. Initial treatment for severe LRIs usually involves empirical broad-
spectrum antibiotics. Guidelines recommend that such therapy should be refined or stopped 
after two to three days, once microbiology results become available 7, 8, but this is often not 
done if the patient is responding well or the laboratory has failed to identify a pathogen. Such 
extensive ‘blind’ use of broad-spectrum antibiotics is wasteful and constitutes poor 
stewardship, given that many patients are infected with susceptible bacteria or a virus. 
Antimicrobial therapy disrupts resident gut flora, and can contribute to the emergence of 
resistant bacteria and Clostridium difficile9, 10.  
 Rapid and accurate microbiological diagnostics could enable tailored treatments and 
reduce overuse of broad-spectrum antibiotics. “Gold standard” culture and susceptibility 
testing is too slow, with typical turnaround times of 48-72 hours and low clinical sensitivity 4, 
11. Molecular methods may help overcome the limitations of culture, as highlighted by the UK 
Government 5-year AMR action plan and the O'Neill report 12-14, by identifying pathogens 
and their antibiotic resistance profiles in a few hours, enabling early targeted therapy and 
supporting antibiotic stewardship. Although nucleic acid amplification tests (including PCR) 
are rapid and highly specific/sensitive, there are limits on multiplexing 15-19 and there is also a 
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constant need to update PCR-based methods to include emerging resistance genes and 
mutations 16, 20, 21. 
 Metagenomic sequencing based approaches have the potential to overcome the 
shortcomings of both culture and PCR, by combining speed with comprehensive coverage of 
all microorganisms present 22, 23. Next-generation sequencting platforms, such as Ion Torrent 
and Illumina, are widely used for metagenomics sequencing, but they require the 
sequencing run to be complete before analysis can begin (although LiveKraken, a recently 
described method, enables analysis of raw Illumina data before the run ends 24). Nanopore 
sequencing (Oxford Nanopore Technologies, ONT) has the advantage of rapid library 
preparation and real-time data acquisition 25, 26. Nanopore sequencing has been used to 
identify viral and bacterial pathogens from clinical samples using targeted approaches and in 
proof-of-concept studies using samples with high pathogen loads e.g. urinary tract infection 
26-28.  
Respiratory specimens present a difficult challenge for metagenomics sequencing, 
owing to variable pathogen load, the presence of commensal respiratory tract flora, and the 
high ratio of host:pathogen nucleic acids present (up to 105:1 in sputum). Nanopore 
sequencing has previously been used for samples from two bacterial pneumonia patients 
without host cell/DNA depletion, but the vast majority of reads were of human origin, with 
only one and two reads aligned to the infecting pathogens, P. aeruginosa and S. aureus, 
respectively 29. It seems likely that a metagenomics method would be improved by 
introducing host DNA depletion. Although commercial kits and published methods are 
available for this purpose (which include differential lysis, human DNA removal and microbial 
DNA enrichment methods 30-33), they do not perform well in complex respiratory samples and 
better methods are needed 34. 
 We present an optimised clinical nanopore metagenomics framework for bacterial 
LRIs that can remove up to 99.99% of host nucleic acid from clinical respiratory samples, 
and enables pathogen and antibiotic resistance gene identification within six hours.  
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RESULTS 
Pilot method development 
A pilot method was tested on respiratory samples from 40 patients with suspected bacterial 
LRI. This method was 91.2% sensitive (95% CI; 75.2-97.7%) and 100% specific (95% CI; 
54.07-100%), not counting additional organisms in culture-positive samples as false 
positives (Table 1), and took 8 hours to perform (Figure 1). Up to 99.9% or ~103 fold (median 
352-fold, interquartile range 144-714; maximum 1024-fold) of host DNA was removed using 
saponin depletion, as measured by qPCR. Microorganisms, including potential respiratory 
pathogens (Online methods), were identified in real-time using ONT’s ‘What’s In My Pot?’ 
(WIMP) pipeline. Additional pathogens, not reported by microbiological culture, were 
detected in 5/40 samples: Moraxella catarrhalis was detected in P8; Escherichia coli in P14; 
H. influenzae in P22 and P30; Klebsiella pneumoniae and M. catarrhalis in P29 (Table 1). 
 
Organisms cultured using routine clinical microbiology were not detected in 3/40 sequenced 
samples. 2/3 samples were mixed infections, where one of the two pathogens present was 
missed by our pilot method – specifically, S. pneumoniae and H. influenzae were not 
detected in P3 and P37 respectively. S. aureus was not detected in the third sample, P34. 
 
Metagenomics protocol optimisation 
We sought to increase sensitivity (8.8% false negative rate) by improving bacterial cell lysis. 
A sample pre-treatment step was introduced (bead-beating or an enzyme cocktail, Online 
methods) to optimise cell lysis. Two culture-positive sputa were used for optimisation 
experiments, one containing S. aureus (Gram-positive) and one containing P. aeruginosa 
(Gram-negative). Neither pre-treatment affected the bacterial DNA yield in the P. aeruginosa 
sample. The enzyme cocktail increased the amount of bacterial DNA in the S. aureus 
sample by approx. 4-fold, and bead-beating by 21-fold, compared with the pilot method, as 
determined by 16S qPCR (Supplementary Table 1a). The increased bacterial DNA yield in 
the bead-beaten S. aureus sample was likely to have been associated with improved lysis of 
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S. aureus, as the pathogen dominated the bacterial community (approx. 80% of reads) 
present in the sample. We included bead-beating in the optimised method. Removal of the 
second DNase treatment and reducing the number of washes shortened the host DNA 
removal protocol from 90 min to 50 min, without affecting efficiency (Supplementary Table 
1a). Additional time was saved by reducing the library preparation PCR extension time from 
six to four minutes. Comparison of the microbial community profile (organisms with ≥0.5% 
classified reads) between libraries produced with four and six minute extension times 
showed only minor differences in the abundance of minor members of the community and a 
small reduction in average read length for the S. aureus sample (<600bp) (Supplementary 
Table 1b). Altogether these changes reduced metagenomic library preparation to 2.5 hours 
with an overall turnaround time of less than four hours before DNA sequencing.  
 
Limit of detection 
The limit-of-detection (LoD) of the optimised method was determined using uninfected 
‘normal respiratory flora’ (NRF) sputum samples (high and low commensal bacterial 
backgrounds in triplicate) spiked with serial ten-fold dilutions of S. aureus and E. coli cultures 
at known cell densities. Each replicate was defined as positive for the spiked ‘pathogen’ if 
present at 1% classified microbial reads (low quality read alignments with a WIMP 
assignment q-score <20 were removed from the analysis). The LoD (2/3 replicates positive) 
was determined to be 100,000 (105) cells for E. coli and 10,000 (104) cells for S. aureus 
when in a high bacterial background (Supplementary Table 2a). The LoD was lower (103 S. 
aureus and E. coli) in sputum samples with a lower bacterial background (Supplementary 
Table 2b). Hence, the LoD of the method ranges from 103-105 CFU/ml, however, different 
levels of background commensal/human DNA could potentially result in different LoDs. 
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Mock community detection 
Our optimised method was tested in triplicate on a panel of common respiratory pathogens 
spiked into an NRF sputum sample (~103-106 CFU/pathogen) to determine whether the 
saponin human DNA depletion method led to inadvertent loss of any bacterial DNA. We 
observed no bacterial DNA loss (average ΔCq <1) for any organisms (E. coli, H. influenzae, 
K. pneumoniae, P. aeruginosa, S. aureus and S. maltophilia) tested except S. pneumoniae 
where there was a 5.7-fold loss, (average ΔCq 2.52) between depleted and undepleted 
samples (Supplementary Table 3). 
 
Optimised method testing 
The optimised method was then tested on 41 respiratory samples from patients with 
suspected bacterial LRIs. A maximum of 104 fold depletion of human DNA (median 600-fold; 
interquartile range 168-1156 fold; maximum 18,054 fold) was observed between depleted 
and undepleted samples, as measured by qPCR (Table 2). The overall sensitivity of the 
optimised method for the detection of respiratory pathogens was 96.6% (95% CI, 80.4-
99.8%) and specificity was 41.7% (95% CI, 16.5-71.4%), not counting additional organisms 
in culture-positive samples as false positives (Table 2). The turnaround time from sample to 
result was approx. 6 hours, including 2 hours MinION sequencing (Supplementary Table 4). 
 
The pathogenic organism reported by routine microbiology was detected together with an 
additional pathogen (not reported by culture) in eight samples: K. pneumoniae in S5, P. 
aeruginosa in S7, M. catarrhalis in S14 and S39, S. pneumoniae in S8 and S15, S. aureus in 
S29 and S. pyogenes in S27 (Table 2). Up to two potentially pathogenic bacteria were also 
observed in seven samples reported as NRF/no significant growth (NSG) by routine 
microbiology i.e. H. influenzae and S. pneumoniae in S10 and S21; S. pneumoniae in S11 
and S28;  M. catarrhalis and H. influenzae in S12; H. influenzae in S31 and E. coli in S32. 
Only one pathogenic organism reported by routine microbiology was not detected using the 
optimised method i.e. S9. This was reported as a mixed infection with P. aeruginosa and E. 
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coli, whereas only E. coli was detected by metagenomics. There were three other mixed 
infections reported by routine microbiology, S27, S38 and S41, and both organisms were 
detected in all three samples using the optimised method.  
 
Confirmatory qPCR was used to establish the presence or absence of the missed/additional 
pathogens detected by metagenomics in 16 samples (1 sample with a missed pathogen, 15 
samples with additional pathogen/s; total of 19 pathogens) and in matched controls i.e. an 
equal number of samples with no evidence of the pathogen by culture or metagenomics 
(Supplementary Table 5). This analysis was performed on DNA extracted from samples that 
did not undergo the depletion process, to rule out depletion as a potential cause of 
missed/additional pathogen detection. The majority of additional pathogens detected by 
metagenomics (12/19) were confirmed by qPCR, which increased the specificity of the 
optimised method to 50% (95% CI, 21.09-78.91% - not counting additional organisms in 
culture-positive samples as false positives (n=2, S5 positive for K. pneumoniae, likely k-mer 
mis-classification of K. oxytoca. S41 positive for E. coli, likely laboratory/kit contamination)). 
qPCR was negative for P. aeruginosa (S9) increasing the sensitivity to 100% (95% CI, 
88.06-100%). 
 
Species-specific gene analysis was performed on all samples positive for pathobionts 
(potentially pathogenic organisms which may reside as commensals in the lung), i.e. H. 
influenzae and S. pneumoniae, which can have closely related non-pathogenic species 
present in the lungs (18 samples containing 20 pathobionts). This confirmatory analysis was 
used to identify k-mer mis-classification of commensal reads as pathogen reads by WIMP. 
Samples containing >1 H. influenzae (siaT) or S. pneumoniae (ply) specific gene alignments 
were considered positive for that organism. The pathobiont-specific gene analysis confirmed 
the absence of H. influenzae/S. pneumoniae in 5/18 samples (also negative by qPCR - see 
previous paragraph) and resulted in metagenomics test sensitivity of 100% (95% CI, 88.06-
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100%) and specificity of 100% (95% CI, 73.54-100%) compared to the culture+qPCR gold 
standard (Supplementary Table 6).  
 
Antibiotic resistance  
The samples tested using the optimised method had little antibiotic resistance, based upon 
routine testing (Supplementary Table 7).  Across the 33 cultivated organisms, just 43 
instances of resistance and intermediate resistance were recorded (Supplementary Table 7), 
with some of these likely reflecting single underlying mechanisms. Sequencing identified 183 
resistance genes across the 41 specimens (with multiple inclusions when ARMA identified 
multiple variants of e.g. blaTEM). 
  
Among the 183 resistance genes, 26 were inherent to the species cultivated (e.g. oqxA/B for 
K. pneumoniae or blaOXA-50 in P. aeruginosa), leaving 157, of which 24 matched the 
phenotype seen (Table 3). These comprised of mecA in both MRSA (S16 and S40), sul1 
and dfrA12 or dfrA17 in both co-trimoxazole-resistant E. coli (S1 and S9), aac(3’)-IIa (and 
IIc) in a tobramycin-resistant E. coli (S9) and a total of 13 blaTEM variants spread recorded 
across two amoxicillin-resistant E. coli (S1 and S35 and two amoxicillin-resistant H. 
influenzae (S18 and S36). A caveat regarding this is that although ARMA flagged multiple 
blaTEM genes, it did not flag blaTEM-1, which was the likeliest variant, given (i) that it is 
considerably the most prevalent type and (ii) that the isolates remained susceptible to 
oxyimino- cephalosporins whereas many of the variants flagged should encode extended-
spectrum variants. Depending on their strength of expression blaTEM or blaOXY may have 
explained non-susceptibility to penicillin/-lactamase inhibitor combinations in 
Enterobacteriales (4/183 genes), but expression is not quantified by ARMA. A blaTEM4 gene 
(1/183) was also found in a ceftazidime- and piperacillin/tazobactam- resistant P. aeruginosa 
(S37); this could explain the phenotype but is unlikely in this species, where -lactam 
resistance most often reflects up-regulation of chromosomal ampC or efflux. There were 
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14/183 genes where any associated resistance could not be confirmed because no relevant 
drug(s) was tested by the clinical laboratory e.g. tet genes were identified in several samples 
(S2, S8, S9, S16, S30, S35, S38 and S39) but tetracycline was not tested against the 
isolates cultured. Sixteen genes detected by ARMA did not match the phenotype of isolates 
cultured, which remained susceptible to relevant antibiotics, and 42 genes were unlikely to 
be from species grown by the laboratory. Finally, multiple genes (56/183) likely originated 
from the normal flora: thus tet(M) and blaTEM-4, each was found in 8/12 NRF/NSG specimens 
whilst mefA and mel were each found in 9/12, as well as in many where the isolates grown 
were unlikely to have hosted these genes. 
 
There were nine samples where phenotypic resistances remained unexplained by resistance 
genes found by ARMA. This included two amoxicillin-resistant M. catarrhalis (S8 and S26), 
where the BRO -lactamase genes were likely to be responsible but were not represented in 
the ARMA database. The remaining seven samples included ampicillin- and co-trimoxazole- 
resistant H. influenzae (S7, S18, S36, S39 and S41), trimethoprim-, ciprofloxacin- 
gentamicin- and fusidic acid- resistant S. aureus (S16) and a K. pneumoniae (S2) resistant 
to both co-amoxiclav and piperacillin/tazobactam but lacking any acquired -lactamase 
gene.   
 
The specificity and sensitivity of the developed method for resistance gene detection was 
not determined as this would have required isolating and sequencing all bacteria (pathogens 
and commensals) present – a prohibitive task.  
 
Reference-based genome assembly 
Two samples containing antibiotic resistant bacteria were chosen as examples to generate 
reference-based genome assemblies directly from the metagenomic data. This analysis was 
performed to illustrate that whole pathogen genomes can be generated directly from 
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respiratory samples for public health and infection control applications. Assemblies were 
generated for an MRSA (S16) and an E. coli resistant to amoxicillin, co-amoxiclav and co-
trimoxazole (S1). The results were compared with those for undepleted controls after two 
and 48 hours of sequencing. Within the first two hours of sequencing the human DNA 
depleted MRSA sample had 47.9x genome coverage with an assembly of 28 contigs 
(GCA_900660255: longest contig = 478718 and N50=400kbp). Genome coverage increased 
to 228.7x after 48hrs of sequencing, with a final assembly consisting of 22 contigs 
(GCA_900660245: longest contig = 481kbp and N50=403kbp). In contrast, the undepleted 
MRSA sample had an assembly of 69 contigs with 3.9x coverage (GCA_900660235: longest 
contig = 47kbp and N50=146kbp) after 2hrs and 33 contigs (17.5x coverage) after 48 hours 
(GCA_900660205: longest contig = 416kbp and N50=263kbp) (Figure 2a). 
 
For the sample positive for resistant E. coli there was 33.5x genome coverage within two 
hours for the depleted sample, with an assembly of 83 contigs (GCA_900660265: longest 
contig = 437kbp and N50=165kbp). Genome coverage increased to 165.7x after 48 hrs with 
the final E. coli assembly having 72 contigs (GCA_900660275: longest contig = 474kbp and 
N50=178kbp). The undepleted sample only produced 0.2x coverage after 2hrs, which 
increased to 1.1x  after 48 hrs of sequencing (Figure 2b). 
 
Time-point analysis 
Using the same sample set as for genome assembly, data from the first two hours of 
sequencing were compared over time for depleted samples and undepleted controls to 
highlight the importance of host depletion for turnaround-time to result. Within 5 min of 
sequencing the depleted MRSA sample (S16) had 1.6x genome coverage compared with 
0.2x coverage for the undepleted control (Figure 2c). The mecA gene was not detected in 
the undepleted sample after 5 min whereas two mecA gene alignments were detected in the 
depleted sample by the same time point (Figure 2d). 
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The depleted E. coli sample (S1) had 5.7x genome coverage within 20 min of sequencing 
compared to 0.06x for the undepleted control (Figure 2e). This E. coli was resistant to 
amoxicillin (blaTEM gene), co-amoxiclav (possibly owing to blaTEM if strongly expressed) and 
co-trimoxazole (sul1 and dfrA17 genes). The blaTEM and dfrA17 genes were not detected in 
the undepleted sample within two hours of sequencing and only one alignment was detected 
for sul1. Conversely, all three resistance genes were detected within 20 min of sequencing 
in the depleted sample and, after two hours, 47 blaTEM, 37 sulf1 and 21 dfrA17 alignments 
were detected (Figure 2f). 
 
Discussion  
Culture-based diagnostics and susceptibility testing, in use for 70 years 35, have limitations 
as guides for the appropriate clinical management of acute infections, mainly because of 
their slow sample-to-result turnaround. Rapid, accurate diagnostics would enable treatment 
with appropriate antibiotics and improve health outcomes and antimicrobial stewardship 
alike. We developed a method to prepare respiratory samples for metagenomics sequencing 
and incorporated it into a nanopore metagenomic sequencing protocol for bacterial pathogen 
and antibiotic resistance gene identification in LRIs within 6h of sample receipt. 
 Our metagenomics workflow for respiratory samples includes host DNA depletion, 
microbial DNA extraction, library preparation, MinION sequencing and real-time data 
analysis. A pipeline was developed (pilot method) and tested on 40 respiratory samples. We 
then optimised our method by shortening the depletion protocol, introducing bead-beating for 
improved microbial lysis, and reducing the library preparation time. Mock community 
analysis demonstrated that the saponin based human DNA depletion method didn’t 
inadvertently remove DNA from common respiratory pathogens, except for S. pneumoniae 
(mean 5.8 fold loss – Supplementary Table 3). It is possible that S. pneumoniae cells may 
have lysed during the host DNA depletion process 36 or might have lysed when grown to 
stationary phase for our mock community experiments. S. pneumoniae was correctly 
identified by metagenomics in five of six culture-positive patients, but it may have been 
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underrepresented in these samples. The time from sample collection to bacterial DNA 
extraction may be crucial for accurate detection of S. pneumoniae. 
The LoD of our optimised method (103-105 cfu/ml) is within the range of culture-
based clinical thresholds applied to respiratory samples. Our optimized method was 96.6% 
sensitive and 41.7% specific compared to culture. Discordant results were investigated using 
pathogen specific probe-based qPCR assays (Supplementary Table 5) which increased 
sensitivity (100%) and specificity (50%). Five of seven remaining discordant samples were 
positive for pathobionts, specifically H. influenzae and/or S. pneumoniae, by metagenomics. 
These false positive detections can be caused by misclassification of reads by WIMP, as k-
mer based read classification can be unreliable at the species level, particularly where 
species in a genus are highly related or share genes 37, 38. To overcome this problem we 
introduced post-hoc pathobiont-specific gene analysis for all H. influenzae and/or S. 
pneumoniae positive samples (n=20 pathobionts in 18 samples). This analysis confirmed 
that the false positive results (n=5) were caused by k-mer misclassification and resulted in 
metagenomics test sensitivity and specificity of 100% compared to culture+qPCR gold 
standard. This issue highlights the need for new methods to accurately identify bacterial 
species from metagenomic data39.  
 To maximise the impact on patient management, identification of clinically relevant 
antibiotic resistance genes as well as the infecting pathogen/s is necessary. In this regard 
the present pipeline has potential but requires refinement. Both MRSA cases were identified 
by the presence of mecA, with no false positives for this gene.  Co-trimoxazole resistance in 
Enterobacteriaceae was accurately identified with detection of sul and dfr genes and these 
were not found in H. influenzae, for which resistance is largely mutational 40, 41.  However, 
genes such as tet(M), mel, mefA and blaTEM were found in all samples where no pathogen 
was grown, suggesting presence in the normal or colonising respiratory flora.  To overcome 
this issue, it will be necessary to associate resistance genes to particular organisms. This 
can be done by examining flanking sequences 42-45 in the c. 3 kb nanopore reads in cases 
where a gene is chromosomally inserted (not plasmid-borne resistance genes), as is usual 
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for transposon borne tet(M) and mefA in streptococci 46-48, including S. pneumoniae 
(Supplementary Figure 1).  
Clinical metagenomics data could also be used to assemble pathogen genomes for 
reference laboratory typing. The quality/depth of the metagenomic data generated by our 
method could enable monitoring of emergence and patient-to-patient spread of pathogens 
and antimicrobial resistance directly from clinical samples in real-time 49, 50. Using PCR for 
respiratory infection diagnosis must be coupled with microbiological culture, otherwise the 
link to phenotype is lost, whereas clinical metagenomics could replace routine culture 
entirely. As viruses are an important cause of LRIs, they can be tested for using PCR, as is 
current routine practice, or our pipeline could be modified to detect viral nucleic acid by 
processing the supernatant fraction after centrifugation of the respiratory sample (Figure 1, 
step 1).  
In conclusion, we report the first rapid clinical metagenomics pipeline for the 
characterization of bacterial LRIs. Pathogens and antibiotic resistance genes can be 
identified in six hours. With additional sequencing time (up to 48 hrs), it provides sufficient 
data for public health and infection control applications. Our protocol is being evaluated in a 
clinical trial (INHALE - http://www.ucl.ac.uk/news/news-articles/1115/181115-molecular-
diagnosis-pneumonia) to evaluate the rapid diagnosis of hospital-acquired and ventilator-
associated pneumonia in comparison with culture and multiplex-PCR. 
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Figure legends 
Figure 1: Schematic representation of the metagenomic pipeline with a turnaround time of approx. six hours (optimised) and approx. eight 
hours (pilot) from sample collection to sample result. 
 
Figure 2:  Bacterial genome assembly, genome coverage and antibiotic gene detection with depleted versus undepleted samples. 
A: MRSA after 48 hours of sequencing. 
B: E. coli after 48 hours of sequencing. 
C: MRSA genome coverage of depleted versus undepleted during two hours of sequencing*. 
D: mecA gene alignment of depleted versus undepleted during two hours of sequencing*. 
E: E. coli genome coverage of depleted versus undepleted during two hours of sequencing*. 
F: blaTEM, sul1 and dfrA17 gene alignment of depleted versus undepleted during two hours of sequencing*. 
*Three independent clinical samples were analysed (an example of a Gram positive and a Gram negative are respresented). 
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Table1: Pilot metagenomic pipeline output compared to routine microbiology culture results. 
 
 
 
 
*Coliform not further identified by culture
Sample Pathogen cultured 
by microbiology 
Pathogen identified from 
metagenomic pipeline 
P22 
 
P. aeruginosa P. aeruginosa 
H. influenzae 
P23 S. aureus S. aureus 
P24 H. influenzae H. influenzae 
P25 H. influenzae H. influenzae 
P26 M. catarrhalis M. catarrhalis 
P27 H. influenzae H. influenzae 
P28 
 
S. pneumoniae  
H. influenzae 
S. pneumoniae 
H. influenzae 
P29 
 
H. influenzae H. influenzae 
K. pneumoniae 
M. catarrhalis 
P30 
 
S. pneumoniae S. pneumoniae 
H. influenzae 
P31 
 
E. aerogenes  
S. aureus 
E. aerogenes 
S. aureus 
P32 P. aeruginosa P. aeruginosa 
P33 S. pneumoniae S. pneumoniae 
P34 S. aureus  
P35 H. influenzae H. influenzae 
P36 S. pneumoniae S. pneumoniae 
P37 
 
H. influenzae  
Coliform* 
 
K. oxytoca 
P38 MRSA MRSA 
P39 S. aureus S. aureus 
P40 H. influenzae  
S. pneumoniae 
H. influenzae 
S. pneumoniae 
Sample Pathogen cultured by 
microbiology 
Pathogen identified from 
metagenomic pipeline 
P1 Coliform* P. mirabilis 
P2 NRF None 
P3 
 
P. aeruginosa 
S. pneumoniae 
P. aeruginosa 
 
P4 NRF None 
P5 Coliform* E. coli 
P6 Coliform* K. pneumoniae 
P7 Coliform* S. marcescens 
P8 H. influenzae H. influenzae 
M. catarrhalis 
P9 H. influenzae H. influenzae 
P10 MRSA MRSA 
P11 Coliform* E. coli 
P12 K. pneumoniae K. pneumoniae 
P13 E. coli E. coli 
P14 
 
K. pneumoniae 
 E. cloacae 
K. pneumoniae 
E. cloacae 
E. coli 
P15 S. aureus S. aureus 
P16 S. aureus S. aureus 
P17 NRF None 
P18 NRF None 
P19 NRF None 
P20 NRF None 
P21 K. pneumoniae K. pneumoniae 
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Table 2. Human and bacterial DNA qPCR results for sputum samples infected by Gram-negative and Gram-positive bacteria with and without 
host nucleic acid depletion 
 
Sample Sample 
type 
Organism cultured 
by microbiology 
 
Organism identified 
from metagenomic 
pipeline 
Sample 
treatment 
Human 
qPCR 
assay (Cq) 
Human 
DNA 
depletion 
(Cq) 
16S rRNA 
gene V3-V4 
fragment 
qPCR assay 
(Cq) 
Bacterial 
gain/loss 
to 
standard 
depletion 
(Cq) 
S1 
 
ETA E. coli E. coli Undepleted 22.62 12.38 
(~104) 
15.60 0.13 
Depleted 35.00 15.73 
S2 
 
Sputum K. pneumoniae 
 
K. pneumoniae 
 
Undepleted 23.73 9.99 
(~103) 
15.63 0.02 
Depleted 33.71 15.65 
S3 
 
Sputum P. aeruginosa 
 
P. aeruginosa 
 
Undepleted 23.05 9.29 
(~103) 
15.46 1.48 
Depleted 32.34 13.98 
S4 
 
Sputum S. marcescens 
 
S. marcescens 
 
Undepleted 26.34 9.93 
(~103) 
16.96 0.52 
Depleted 36.27 17.48 
S5 Sputum K. oxytoca 
 
K. oxytoca Undepleted 22.96 8.58 
(~103) 
12.67 0.64 
K. pneumoniae Depleted 31.54 12.03 
S6 
 
Sputum S. aureus 
 
S. aureus 
 
Undepleted 22.31 9.41 
(~103) 
19.11 1.57 
Depleted 31.72 17.54 
S7 
 
Sputum H. influenzae 
 
H. influenzae Undepleted 25.47 9.53 
(~103) 
21.44 0.43 
P. aeruginosa Depleted 35.00 21.87 
S8 
 
Sputum M. catarrhalis 
 
M. catarrhalis Undepleted 22.72 9.17 
(~103) 
16.9 0.66 
S. pneumoniae Depleted 31.89 17.56 
S9 
 
Sputum P. aeruginosa  
& E. coli 
 
 Undepleted 23.89 11.11 
(~104) 
19.58 3.26 
E. coli Depleted 35 22.84 
S10 
 
Sputum NSG 
 
H. influenzae Undepleted 23.46 8.6 
(~103) 
14.12 2.39 
S. pneumoniae Depleted 32.06 16.51 
S11 
 
Sputum NRF 
 
S. pneumoniae Undepleted 25.77 9.23 
(~103) 
17.96 1.92 
Depleted 35.00 19.88 
S12 
 
Sputum NRF 
 
H. influenzae Undepleted 22.5 8.92 
(~103) 
17.61 0.05 
M. catarrhalis Depleted 31.42 17.56 
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S13 
 
Sputum S. marcescens 
 
S. marcescens 
 
Undepleted 22.48 7.11 
(~102) 
12.77 0.79 
Depleted 29.59 11.98 
S14 
 
Sputum S. aureus  
 
S. aureus  Undepleted 23.17 7.68 
(~102) 
13.83 0.96 
M. catarrhalis Depleted 30.85 14.79 
S15 
 
Sputum S. aureus 
 
S. aureus Undepleted 22.66 8.47 
(~103) 
18.73 0.08 
S. pneumoniae Depleted 31.13 18.65 
S16 
 
Sputum MRSA MRSA Undepleted 25.51 6.43 
(~102) 
15.32 0.24 
Depleted 31.94 15.56 
S17 
 
Sputum NRF 
 
None Undepleted 23.51 9.64 
(~103) 
19.55 1.17 
Depleted 33.15 20.72 
S18 
 
Sputum H. influenzae 
 
H. influenzae 
 
Undepleted 27.14 7.86 
(~102) 
12.89 2.21 
Depleted 35.00 15.10 
S19 
 
Sputum NRF 
 
None Undepleted 22.63 11.18 
(~103) 
19.69 0.69 
Depleted 33.81 19.00 
S20 
 
Sputum H. influenzae 
 
H. influenzae Undepleted 22.44 10.03 
(~103) 
14.99 1.19 
Depleted 32.47 16.18 
S21 
 
Sputum NRF 
 
H. influenzae Undepleted 24.58 10.42 
(~103) 
16.60 0.82 
S. pneumoniae Depleted 35.00 17.42 
S22 
 
Sputum NRF 
 
None Undepleted 22.71 9.22 
(~103) 
14.62 0.39 
Depleted 31.93 15.01 
S23 
 
Sputum H. influenzae 
 
H. influenzae 
 
Undepleted 24.82 10.18 
(~103) 
16.80 1.84 
Depleted 35.00 18.64 
S24 
 
Sputum H. influenzae  
 
H. influenzae 
 
Undepleted 22.24 10.17 
(~103) 
15.70 1.63 
Depleted 32.41 17.33 
S25 
 
Sputum H. influenzae 
 
H. influenzae 
 
Undepleted 25.52 6.26 
(~102) 
16.59 2.67 
Depleted 31.79 19.26 
S26 
 
Sputum M. catarrhalis 
 
M. catarrhalis 
 
Undepleted 23.47 11.53 
(~104) 
19.26 0.74 
Depleted 35.00 20.00 
S27 
 
Sputum H. influenzae  
& S. aureus 
H. influenzae Undepleted 32.74 2.26 
(~5) 
23.19 7.92 
S. aureus Depleted 35.00 15.27 
S. pyogenes 
S28 
 
Sputum NRF S. pneumoniae Undepleted 24.46 10.54 
(~103) 
22.28 2.80 
Depleted 35.00 25.08 
S29 Sputum P. aeruginosa P. aeruginosa Undepleted 24.05 5.11 19.81 2.04 
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  S. aureus Depleted 29.13 (~102) 17.77 
S30 
 
BAL P. aeruginosa 
 
P. aeruginosa Undepleted 29.93 5.07 
(~33) 
22.68 0.00 
Depleted >35.00 22.68 
S31 
 
Sputum NRF 
 
H. influenzae Undepleted 21.57 8.26 
(~103) 
19.79 1.65 
Depleted 29.83 21.44 
S32 
 
Sputum NSG E. coli Undepleted 25.56 8.68 
(~103) 
15.98 0.47 
Depleted 34.24 16.45 
S33 
 
Sputum NRF 
 
None Undepleted 21.73 10.04 
(~103) 
20.69 0.81 
Depleted 31.77 21.50 
S34 
 
Sputum NSG 
 
None Undepleted 25.17 5.40 
(~102) 
22.92 0.01 
Depleted 30.57 22.93 
S35 
 
Sputum E. coli 
 
E. coli 
 
Undepleted 21.11 5.18 
(~102) 
16.49 0.58 
Depleted 26.29 17.07 
S36 
 
Sputum H. influenzae 
 
H. influenzae 
 
Undepleted 22.58 9.70 
(~103) 
16.51 2.00 
Depleted 32.28 18.51 
S37 
 
Sputum P. aeruginosa 
 
P. aeruginosa 
 
Undepleted 21.56 11.69 
(~104) 
15.25 1.80 
Depleted 33.24 13.45 
S38 
 
Sputum S. aureus  
& P. aeruginosa 
S. aureus  Undepleted 20.76 6.87 
(~102) 
23.83 3.17 
P. aeruginosa Depleted 27.63 20.66 
S39 
 
Sputum H. influenzae 
 
H. influenzae Undepleted 23.82 11.18 
(~103) 
14.45 2.79 
M. catarrhalis Depleted 35.00 17.24 
S40 
 
ETA MRSA 
 
MRSA Undepleted 21.69 4.28 
(~19) 
19.91 1.62 
Depleted 25.97 18.29 
S41 Sputum H. influenzae  
& S. aureus 
H. influenzae  Undepleted 20.86 14.14 
(~104) 
16.71 6.85 
S. aureus Depleted 35.00 23.56 
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Table 3.  Resistance genes found by ARMA in relation to pathogens grown: Optimised 
pipeline (41 samples; 183 genes detected) 
 
ARMA vs. culture result No. 
genes 
Principal examples 
Gene endogenous in species 26 
Mostly efflux components; also blaOXA-
50, aph(3’)-IIb and catB7 from P. 
aeruginosa and aac(6’)-Ic from S. 
marcescens  
Match to observed R 24 
Variously including mecA in MRSA, 
blaTEM in Enterobacteriaceae and H. 
influenzae, also sul1 and dfr 
determinants for E. coli 
Partial match to observed 
resistances 
4 
Instances where blaTEM was found but 
where MinION flagged an ESBL-
encoding variant, usually blaTEM-4, but 
where the phenotype indicated only a 
classical penicillinase, without oxyimino-
cephalosporin resistance  
Unlikely match to observed 
phenotype 
1 
P. aeruginosa with blaTEM resistant to 
piperacillin/tazobactam and ceftazidime 
– see text 
Possibly present, but relevant drug 
not tested by clinical lab 
14 
Commonly (i) where tet(C) found but lab 
tested doxycycline, which is not a 
substrate for this pump, or (ii) where 
streptomycin, kanamycin and macrolide 
determinants were found in gram-
 24 
negative bacteria but these drugs were 
not tested, as not relevant to therapy.  
Does not match phenotype of 
isolate 
16 
Mostly where blaTEM (as blaTEM-4) was 
recorded but the isolate (commonly H. 
influenzae) was susceptible to 
penicillins as well as cephalosporins, or 
where tet(M) was found together with a 
tetracycline-susceptible S. aureus 
Genes unlikely to be from species 
grown by the laboratory 
42 
Mostly gram-positive-associated genes 
when a gram-negative organism was 
grown, or vice versa: commonly 
including tet(M) and mefA 
Gene recorded in a specimen with 
no pathogen grown 
56 
Mostly tet, mef mel, blaTEM-4 
determinants, likely to be associated 
with normal flora 
Total 183  
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ONLINE METHODS  
Ethics  
This study used excess respiratory samples, after routine microbiology diagnostic tests had 
been performed, from patients with suspected LRIs such as persistent (productive) cough, 
bronchiectasis, CAP/HAP, cystic fibrosis and exacerbation of chronic obstructive pulmonary 
disease (COPD, emphysema/chronic bronchitis). The UCL Infection DNA Bank (REC 
reference 12/LO/1089) approved use of excess respiratory samples for the study. No patient 
identifiable information was collected, hence informed consent was not required. The only 
data collected were routine microbiology results, which detailed the pathogen(s) identified 
and their antibiotic susceptibility profiles.  
 
Definitions 
‘Respiratory pathogens’ or ‘pathogens’ are defined in this study as common causes of 
respiratory infection, in order to differentiate them from commensal organisms. Respiratory 
pathogens identified in this study were: E. aerogenes, E. cloacae complex, E. coli, H. 
influenzae, K. oxytoca, K. pneumoniae, M. catarrhalis, P. mirabilis, P. aeruginosa, S. 
marcescens, S. aureus, S. pneumoniae, S. pyogenes. A list of all microorganisms identified 
in all samples tested using the optimised method (above our thresholds) are listed in 
supplementary table 8. Some of these organisms, not defined as common pathogens here, 
could be considered pathogens in some clinical contexts. 
 
Routine clinical microbiological investigation  
Respiratory samples including sputum, endotracheal secretions and ETAs were treated with 
sputasol (Oxoid-SR0233) in a 1:1 ratio before being incubated for a minimum of 15 min at 37  
C. Sputasol-treated respiratory samples (10 µl) were inoculated into 5 ml of sterile water 
and mixed (hence the limit of detection of culture is 105 CFU/ml). Following this, 10 µl of 
sample was streaked onto blood, chocolate and cysteine lactose electrolyte deficient (CLED) 
agar. BAL samples were not treated with sputasol; instead they were centrifuged to 
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concentrate bacterial cells for a minimum of 10 min at 3000 rpm. BALs did not undergo 
further dilution and were streaked directly onto the agar plate. Depending on clinical details 
and the source of the specimen, other agar plates (including sabouraud, mannitol salt and 
Burkholderia cepacia selective agar) were additionally used. 
 
All inoculated agar plates were incubated at 37 C overnight and then examined for growth 
with the potential for re-incubation up to 48 hours. If any significant organism was grown, 
then antibiotic susceptibility testing by agar diffusion using EUCAST methodology was 
performed. The laboratory’s Standard Operating Procedure is based on the Public Health 
England UK Standards for Microbiology Investigations B 57: Investigation of bronchoalveolar 
lavage, sputum and associated specimens 51. 
 
Sample collection and storage  
The excess respiratory samples (sputa, ETA, BAL) were collected after culture and 
susceptibility testing at Norfolk and Norwich University Hospitals (NNUH) Microbiology 
Department (described above) and stored at 4 °C prior to testing. They were indicated by 
clinical microbiology to contain bacterial pathogen(s), NRF or to have yielded NSG. Forty 
samples (n=34 positive and n=6 NRF samples, comprising 34 sputa, four BALs and two 
ETAs) were used to test the Pilot method and another 41 (n=29 suspected LRI, n=9 NRF 
and n=3 NSG samples, comprising 38 sputa, one BAL and two ETAs) were used to test the 
Optimised pipeline. 
 
Pilot method: Host DNA Depletion 
Respiratory samples (400 µl) were centrifuged at 8000 xg for 5 min, after which the 
supernatant was carefully removed and the pellet resuspended in 250 µl of PBS. The 
saponin-based differential lysis method was modified from previously reported saponin 
methods 33, 52. Saponin (Tokyo Chemical Industry- S0019) was added to a final 
concentration of 2.5 % (200 µl of 5 % saponin), mixed well and incubated at room 
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temperature (RT) for 10 min to promote host cell lysis. Following this incubation, 350 µl of 
water was added and incubation was continued at RT for 30 s, after which 12 µl of 5 M NaCl 
was added to deliver an osmotic shock, lysing the damaged host cells. Samples were next 
centrifuged at 6000 xg for 5 min, with the supernatant removed and the pellet resuspended 
in 100 µl of PBS.  HL-SAN buffer (5.5 M NaCl and 100 mM MgCl2 in nuclease-free water) 
was added (100 µl) with 5 µl HL-SAN DNase (25,000 units, Articzymes - 70910-202) and 
incubated for 15 min at 37 °C with shaking at 800 RPM for host DNA digestion. An additional 
2 µl of HL-SAN DNase was added to the sample, which next was incubated for a further 15 
min at 37 °C with shaking at 800 RPM. Finally, the host-DNA depleted samples were 
washed three times with decreasing volumes of PBS (300 µl, 150 µl, 50 µl). After each 
wash, the sample was centrifuged at 6000 xg for 3 min, the supernatant discarded and the 
pellet resuspended in PBS.  
 
Pilot method: Bacterial Lysis and DNA Extraction 
After the final wash step of the host depletion, the pellet was resuspended in 380 µl of 
bacterial lysis buffer (Roche UK- 4659180001) and 20 µl of proteinase K (>600mAu/ml) 
(Qiagen -19133) was added before incubation at 65 °C for 10 min with shaking at 800 RPM 
(on an Eppendorf Thermomixer). Nucleic acid was then extracted from samples using the 
Roche MagNAPure Compact DNA_bacteria_V3_2 protocol (MagNA pure compact NA 
isolation kit I, Roche UK- 03730964001) on a MagNA Pure Compact machine (Roche UK- 
03731146001).  
 
Optimised method: Host DNA Depletion (Figure 1) 
The optimized method sought to improve and shorten some steps. Specifically, after the first 
5 min centrifugation at 8000 x g, up to 50 µl of supernatant was left so as not to disturb the 
pellet (final saponin conc. 2.2-2.5%). Instead of performing two rounds of host DNA 
digestion, the amount of HL-SAN DNase was increased up to 10 µl and a single incubation 
of 15 min at 37 °C was carried out with shaking at 800 RPM on an Eppendorf Thermomixer. 
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Finally, the number of washes was reduced to two with increasing volumes of PBS (800 µl 
and 1 ml). 
 
Optimised method: Bacterial Lysis and DNA Extraction (Figure 1) 
After the final wash, the pellet was re-suspended in 500 µl of bacterial lysis buffer (Roche 
UK - 4659180001), transferred to a bead-beating tube (Lysis Matrix E, MP Biomedicals -
116914050) and bead-beaten at maximum speed (50 oscillations per second) for 3 min in a 
Tissue Lyser bead-beater (Qiagen - 69980). This ensured the release of DNA from difficult-
to-lyse organisms (e.g. S. aureus). The sample was centrifuged at 20,000 xg for 1 min and 
~230 µl of supernatant was transferred to a fresh Eppendorf tube. The volume was topped-
up with 170 µl of bacterial lysis buffer and 20 µl of proteinase K (>600 mAu/ml, Qiagen -
19133) was added. Samples were then incubated at 65 °C for 5 min with shaking at 800 
RPM on an Eppendorf Thermomixer. DNA was extracted from samples using the Roche 
MagNAPure Compact DNA_bacteria_V3_2 protocol (MagNA pure compact NA isolation kit I, 
Roche UK - 03730964001) on a MagNA Pure Compact machine (Roche UK - 
03731146001).  
 
DNA quantification and quality control 
DNA quantification was performed using the high sensitivity dsDNA assay kit (Thermo 
Fisher - Q32851) on the Qubit 3.0 Fluorometer (Thermo Fisher - Q33226). DNA quality and 
fragment size (PCR products and MinION libraries) were assessed using the TapeStation 
2200 (Agilent Technologies - G2964AA) automated electrophoresis platform with the 
Genomic ScreenTape (Agilent Technologies - 5067-5365) and a DNA ladder (200 to 
>60,000 bp, Agilent Technologies - 5067-5366). 
 
MinION Library Preparation and Sequencing  
MinION library preparation was performed according to the manufacturer’s instructions for (i) 
the Rapid Low-Input by PCR Sequencing Kit (SQK-RLI001), (ii) the Rapid Low-Input 
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Barcoding Kit (SQK-RLB001) or (iii) the Rapid PCR Barcoding Kit (SQK-RPB004) with minor 
alterations as follows. For single sample sequencing runs using the SQK-RLI001 kit, 10 ng 
of the MagNA Pure-extracted DNA were used for the tagmentation/fragmentation reaction, 
where DNA was incubated at 30 °C for 1 min and at 75 °C for 1 min. The PCR reaction was 
run as per the manufacturer’s instructions; however, the number of PCR cycles was 
increased to 20. For multiplexed runs, SQK-RLB001 and SQK-RPB004 kits were used. A 
1.2x AMPure XP bead (Beckman Coulter-A63881) wash was introduced after the MagNA 
Pure DNA extraction and prior to library preparation for multiplexed runs and DNA was 
eluted in 15 µl of nuclease-free water. Modifications for the library preparation were i) 10 ng 
of input DNA and 2.5 µl of FRM were used for the tagmentation/fragmentation reaction and 
nuclease-free water was used to make the volume up to 10 µl, ii) for the PCR reaction, 25 
cycles were used and the reaction volume was doubled. All samples run using the Pilot 
method used a 6 min extension time, whereas the Optimised method used a reduced 
extension time of 4 min. When multiplexing, PCR products were pooled together in equal 
concentrations, then subjected to a 0.6x AMPure XP bead wash and eluted in 14 µl of the 
buffer recommended in the manufacturer’s instructions (10 μL 50 mM NaCl, 10 mM Tris.HCl 
pH8.0). Sequencing was performed on the MinION platform using R9.4, R9.5 or R9.4.1 flow 
cells.  The library (50-300 fmol) was loaded onto the flow cell according to the 
manufacturer’s instructions. ONT MinKNOW software (versions 1.4-1.13.1) was used to 
collect raw sequencing data and ONT Albacore (versions 1.2.2-2.1.10) was used for local 
base-calling of the raw data after sequencing runs were completed. The MinION was run for 
up to 48 hours with WIMP/ARMA analysis performed on the first six folders (~24,000 reads) 
for Pilot method samples and the first two hours of data for all Optimised method samples. 
 
Quantitative PCR (qPCR) assays 
Probe or SYBR Green based qPCR was performed on samples to detect and quantify human 
DNA, DNA targets for specific pathogens (E. coli, H. influenzae, K. pneumoniae, M. 
catarrhalis, P. aeruginosa, S. aureus, Stenotrophomonas maltophilia, S. pneumoniae and S. 
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pyogenes) and the bacterial 16S rRNA V3-V4 gene fragment. All qPCR assays were 
performed on a Light Cycler® 480 Instrument (Roche). Details of primer sequences and 
targets can be found in Supplementary Table 9 (oligonucleotides were supplied by Sigma. 
 
For all probe-based qPCR reactions, the master mix consisted of 10 µl LightCycler 480 probe 
master (2X), 0.5 µl each of reverse and forward primer (final conc. 0.25 µM) and 0.4 µl probe 
(final conc. 0.2 µM). For all SYBR-Green-based qPCR reactions, the master mix consisted of 
10 µl LightCycler 480 SYBR Green I master (2x) and 1 µl of each forward and reverse primer 
(final conc. 0.5 µM). To the PCR mix, 2 µl of DNA template and nuclease-free water to a total 
volume of 20 µl were added. The qPCR conditions were: pre-incubation at 95 °C for 5 min, 
amplification for 40 cycles at 95 °C for 30 sec, 55 °C for 30 sec and 72 °C for 30 sec, with a 
final extension at 72 °C for 5 min. Melt curves analysis (for SYBR-Green qPCR) was 
performed at 95 °C for 5 sec, 65 °C for 1 min, ramping to 95 °C at 0.03 °C/s in continuous 
acquisition mode, followed by cooling to 37 °C. All probe-based confirmatory qPCR used the 
following conditions: pre-incubation at 95 °C for 15 min, amplification for 40 cycles at 94 °C 
for 15 sec and 60 °C for 1 min. 
 
Example Limit of detection 
The LoD of the Optimised method was determined for the detection of one Gram-positive 
and one Gram-negative bacteria in sputum using serial dilutions (10 –105 cfu/ml) of cultured 
E. coli (H141480453) and S. aureus (NCTC 6571) spiked into NRF sputum samples with 
high and low bacterial commensal backgrounds (as determined by 16S qPCR). The serial 
dilutions were made in sterile PBS and plated in triplicate on LB agar to determine colony 
forming units (CFU) per ml. The same dilutions were used to spike an NRF sputum sample 
for LoD experiments. Detection and quantification of bacterial DNA was performed using 
probe-based qPCR assays and MinION sequencing. 
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Mock community experiments 
Clinical isolates from respiratory samples were used to generate a mock community consisting 
of S. pneumoniae, K. pneumoniae, H. influenzae, S. maltophilia and P. aeruginosa. E. coli 
and S. aureus strains were also included (H141480453 and NCTC 6571 respectively). 
Pathogens (E. coli and S. aureus in 10 ml Luria-Broth and K. pneumoniae, P. aeruginosa and 
S. maltophilia in 10 ml Tryptic Soy Broth (TSB)) were cultured overnight at 37 °C with shaking 
at 180 RPM. H. influenzae (in 10 ml TSB) and S. pneumoniae (in 10 ml Brain Heart Infusion 
Broth) were cultured statically at 37 °C with 5% CO2 in an aerobic incubator. Cultured 
pathogens were then spiked into an NRF sample (~103-106 CFU/pathogen). The spiked 
samples were then tested in triplicate with the Optimised method, to determine if saponin 
depletion resulted in any inadvertent lysis of pathogens and loss of their DNA. All spiked 
samples were processed alongside undepleted controls. Probe or SYBR Green-based qPCR 
assays were used to determine the relative quantity of each spiked pathogen in depleted and 
undepleted spiked sputum samples.  
 
Human read removal 
Human reads were removed from basecalled FASTQ files using minimap2 to align to the 
human hg38 genome (GCA_000001405.15 “soft-masked” assembly) prior to Epi2ME 
analysis. Only unassigned reads were exported to a bam file using Samtools (-f 4 parameter). 
Non-human reads were converted back to FASTQ format using bam2fastx. These FASTQ 
files were processed for pathogen identification using WIMP and antibiotic resistance gene 
detection with ARMA. Further downstream analysis for genome coverage was performed 
using minimap2 with default parameters for long-read data (-a -x map-ont) and visualised 
using qualimap (used for time-point analysis). 
 
Pathogen identification and antibiotic resistance gene detection  
The EPI2ME Antimicrobial Resistance pipeline (ONT, versions 2.59.1896509) was used for 
initial analysis of MinION data for the identification of bacteria present in the sample and any 
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associated antimicrobial resistance genes. Within this pipeline, WIMP (What’s in my Pot – 
rev. 3.3.1) supports the identification of bacteria, viruses, fungi, archaea and human reads 
and was used for respiratory pathogen identification. WIMP utilises ‘Centrifuge’, a k-mer-
based read identification tool based on a Burrows-Wheeler transform and the Ferragina-
Manzini index,  to identify reads using the RefSeq database 53. ARMA (Antimicrobial 
Resistance Mapping Application – rev. 1.1.5) is also included in the Antimicrobial Resistance 
pipeline. ARMA utilises the CARD database for antibiotic resistance gene detection and 
identification by aligning input reads using minimap2 (alignments reported at >75% accuracy 
and >40% horizontal coverage 54). Full manuals are publicly available for WIMP and ARMA 
on the ONT website (https://nanoporetech.com/EPI2ME-amr). NanoOK/NanoOK RT 45, 55 are 
publically available tools which identify microbes and antimicrobial resistance using 
basecalled nanopore data, providing similar outputs to those from ONTs WIMP and ARMA 
software.  
 
Initial analysis of respiratory metagenomic data revealed that thresholds would be required 
to improve the accuracy of results. Thresholds, in terms of number of bacteria per ml of body 
fluid, are applied in clinical microbiology laboratories for some infections including those of 
the urinary and respiratory tracts. The same approach was required for metagenomics. The 
clinical thresholds used for respiratory samples is typically 105 pathogens/ml (range 103-
105/ml dependent on sample type) and is achieved by sample dilution 51. We routinely 
applied thresholds at ≥1% of classified reads, with a WIMP assignment q-score ≥20 (within 
.csv files). We chose these thresholds to: censor reads arising from pipeline contaminants; 
remove barcode leakage between samples on multiplexed runs (ONT’s Flongle 
(https://nanoporetech.com/products/comparison), an adapter for single use flowcells 
designed for diagnostic applications, should overcome this issue) and; remove low quality 
WIMP alignments, which result in misclassified reads. Antibiotic resistance genes were 
reported if >1 gene alignment was present using the ‘clinically relevant’ parameter within 
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ARMA. This parameter currently reports resistance genes, acquired and chromosomal, but 
not resistance mutations/SNPs. 
 
Pathobiont-specific gene analysis 
Species-specific gene alignments were performed on samples positive for H. influenzae or S. 
pneumoniae by metagenomics (above our thresholds). Reads (after human DNA removal) 
were aligned to pathobiont-specific genes (siaT, ply – chosen from a literature search for 
species-specific genes in H. influenzae56 and S. pneumoniae15, respectively) using minimap2 
with default parameters for long-read data (-a -x map-ont) and the number of mapped reads 
visualised using qualimap. If a sample contained >1 copy of the specific gene it was 
considered positive for the species.  
 
Bacterial genome assembly 
Genome assembly was performed first using Fast5-to-Fastq to remove reads shorter than 
2000 bp and with a mean quality score lower than seven (https://github.com/rrwick/Fast5-to-
Fastq). Porechop was used to remove sequencing adapters in the middle and/or the ends of 
each read, and re-identification of barcodes was carried out for each multiplexed sample 
(v0.2.3) (https://github.com/rrwick/Porechop). Filtered reads were aligned to a reference 
genome (chosen based on WIMP classification of pathogen reads) using minimap2 with 
default parameters for ONT long-read data (v2.6-2.10) 57. Finally, Canu was used to 
assemble mapped reads into contigs using this long-read sequence correction and 
assembly tool (v1.6) 58, 59. BLAST Ring Image Generator (BRIG) was used for BLAST 
comparisons of the genome assemblies generated 60.  
 
Data availability 
All clinical sample sequence data and assemblies are available via European Nucleotide 
Achive (ENA) under study accession number PRJEB30781.  
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